New Data Presented at CORA 2025 Conference Highlights Clinical Potential of Chemomab's Nebokitug in Systemic Sclerosis

Core Viewpoint - Chemomab Therapeutics is advancing its investigational drug nebokitug (CM-101) as a potential treatment for systemic sclerosis (SSc), supported by new preclinical and clinical data to be presented at CORA 2025 [1][3] Company Overview - Chemomab Therapeutics is a clinical-stage biotechnology company focused on developing innovative therapeutics for fibro-inflammatory diseases with significant unmet medical needs [12] - The company has developed nebokitug, a first-in-class dual activity monoclonal antibody that neutralizes CCL24, a protein implicated in fibrosis and inflammation [12] Drug Mechanism and Evidence - Nebokitug targets CCL24, which is a key driver of fibro-inflammatory conditions, including SSc and primary sclerosing cholangitis (PSC) [2][7] - Preclinical studies indicate that blocking CCL24 can reduce inflammatory and fibrotic injuries in the lungs, skin, and vasculature associated with SSc [2] - An investigator-sponsored study demonstrated that nebokitug led to significant reductions in inflammatory biomarkers in patients with acute lung injury, relevant to SSc [2] Clinical Data and Trials - The upcoming presentation at CORA 2025 will include findings from a study assessing nebokitug's effects on immune cells in SSc patients, reinforcing the therapeutic rationale for targeting CCL24 [3][6] - A 2024 peer-reviewed publication highlighted strong associations between CCL24 levels and severe clinical manifestations of SSc, indicating that higher CCL24 levels correlate with worse outcomes [4] - Positive results from the Phase 2 SPRING trial in PSC further support the potential of nebokitug, showing reductions in key fibro-inflammatory biomarkers [5] Regulatory Status - Nebokitug has received FDA and EMA Orphan Drug designations for both PSC and SSc, as well as FDA Fast Track status for PSC treatment [7][12] - The SSc program has an open U.S. Investigational New Drug (IND) application, indicating ongoing efforts to advance clinical trials [7][12] Disease Context - Systemic sclerosis (SSc) is a rare autoimmune disease characterized by severe fibrosis and inflammation, with no approved disease-modifying therapies currently available [8] - The disease predominantly affects women and has a median survival of only 10 years, highlighting the urgent need for effective treatments [8]